5.54

2.58% 0.0226

Cns Pharmaceuticals Inc (CNSP)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.5174

Offen:

$5.7

24-Stunden-Volumen:

2,304

Relative Volume:

0.08

Marktkapitalisierung:

$8.46M

Einnahmen:

Nettoeinkommen (Verlust:

$-16.49M

KGV:

-0.187

EPS:

-29.6295

Netto-Cashflow:

$-15.24M

1W Leistung:

-2.92%

1M Leistung:

+11.64%

6M Leistung:

+81.99%

1J Leistung:

-9.66%

1-Tages-Spanne:

$5.4774

$5.79

1-Wochen-Bereich:

$5.44

$6.1899

52-Wochen-Spanne:

$1.90

$10.59

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Firmenname

Cns Pharmaceuticals Inc

Sektor

Healthcare (1088)

Branche

Biotechnology (605)

Telefon

1-800-946-9185

Adresse

2100 WEST LOOP SOUTH, HOUSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

CNSP's Discussions on Twitter

Compare CNSP vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CNSP Cns Pharmaceuticals Inc	5.79	8.77M	0	-16.49M	-15.24M	-29.63
VRTX Vertex Pharmaceuticals Inc	543.11	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	791.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,029.53	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.80	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.93	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-12-28	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2020-08-24	Eingeleitet	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten

Aug 19, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026

Aug 18, 2026

Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo

Aug 18, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com

Aug 18, 2026

CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan

Aug 18, 2026

CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan

Aug 18, 2026

Aug 17, 2026

Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com

Aug 17, 2026

Aug 16, 2026

CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan

Aug 14, 2026

Aug 13, 2026

CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn

Aug 13, 2026

Aug 12, 2026

CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView

Aug 12, 2026

CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView

Aug 12, 2026

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com

Aug 12, 2026

CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView

Aug 12, 2026

CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year - Bitget

Aug 12, 2026

Aug 11, 2026

CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn

Aug 11, 2026

Aug 10, 2026